This article previews a clinical update on an endoscopic procedure aimed at sustaining GLP-1–related weight loss, with context on company milestones and next-step data.
Key Takeaways
- Weight regain after discontinuation is common and well documented
- Company’s REMAIN-1 programme is structured around three cohorts studied under a single investigational device exemption
- Equivalent to maintaining roughly 78% of their prior GLP-1-induced weight loss